NAMS vs ESPR vs MDGL

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus -50. 6% for NewAmsterdam Pharma Company N. V. (NAMS). Analysts rate NewAmsterdam Pharma Company N. V. (NAMS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +290. 8%, compared to -85. 1% for Esperion Therapeutics, Inc. (ESPR). Over 10 years, the gap is even starker: MDGL returned +37. 4% versus ESPR's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.

(MDGL) is the lower-risk stock at 0. 62β versus Esperion Therapeutics, Inc. 's 2. 32β — meaning ESPR is approximately 272% more volatile than MDGL relative to the S&P 500. On balance sheet safety, NewAmsterdam Pharma Company N. V. (NAMS) carries a lower debt/equity ratio of 0% versus 59% for Madrigal Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus -50. 6% for NewAmsterdam Pharma Company N. V. (NAMS). On earnings-per-share growth, the picture is similar: Esperion Therapeutics, Inc. grew EPS 60. 7% year-over-year, compared to 31. 6% for NewAmsterdam Pharma Company N. V.. Over a 3-year CAGR, ESPR leads at 74. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Esperion Therapeutics, Inc.

(ESPR) is the more profitable company, earning -5. 6% net margin versus -905. 7% for NewAmsterdam Pharma Company N. V. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ESPR leads at 15. 0% versus -1002. 9% for NAMS. At the gross margin level — before operating expenses — NAMS leads at 99. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62)). Esperion Therapeutics, Inc. (ESPR) carries a higher beta of 2. 32 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDGL: +37. 4%, ESPR: -79. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NAMS is a small-cap quality compounder stock; ESPR is a small-cap high-growth stock; MDGL is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.